Ian M. Coupar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ian M. Coupar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Helen R. Irving
La Trobe Institute for Molecular Science, La Trobe University, Bendigo, VIC 3550, Australia
3 shared publications Andrew C Gray
Department of Pharmaceutical Biology and Pharmacology, Faculty of Pharmacy, Victorian College of Pharmacy, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia
1 shared publicationBinh L. T. Tran
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University (Parkville Campus) , 381 Royal Parade, Parkville, Victoria 3052
1 shared publicationD.L. Hancock
Victorian College of Pharmacy, Monash University, Department of Pharmaceutical Biology and Pharmacology, Parkville Victoria, Australia
1 shared publicationHaihuang Liu
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University, Parkville, Australia
1 shared publicationJuliana L Di Iulio
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University (Parkville Campus), Parkville, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 5 (4) , 224-231
Human 5-HT4 and 5-HT7 Receptor Splice Variants: Are they Important?
G-protein-coupled receptors (GPCRs), which are encoded by > 300 genes in the human genome, are by far the largest class of targets for modern drugs. These macromolecules display inherent adaptability of function, which is partly due to the production of different forms of the receptor protein. These are commonly called ‘isoforms’ or ‘splice variants’ denoting the molecular process of their production/ assembly. Not all GPCRs are expressed as splice variants, but certain subclasses of 5-HT receptors are for example, the 5-HT4 and 5-HT7 receptors. There are at least 11 human 5-HT4 and three h5-HT7 receptor splice variants. This review describes their discoveries, nomenclature and structures. The discovery that particular splice variants are tissue specific (or prominent) has highlighted their potential as future drug targets. In particular, this review examines the functional relevance of different 5-HT4 and 5-HT7 receptor splice variants. Examples are given to illustrate that splice variants have differential modulatory influences on signalling processes. Differences in agonist potency and efficacies and also differences in desensitisation rates to 5-HT occur with both 5-HT4 and 5-HT7 receptor splice variants. The known and candidate signalling systems that allow for splice variant specific responses include GPCR interacting proteins (GIPs) and GPCR receptor kinases (GRKs) which are examined. Finally, the relevance of 5-HT receptor splice variants to clinical medicine and to the pharmaceutical industry is discussed.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 5 (4) , 224-231
Open AccessHuman 5-HT4 and 5-HT7 Receptor Splice Variants: Are they Important?
G-protein-coupled receptors (GPCRs), which are encoded by > 300 genes in the human genome, are by far the largest class of targets for modern drugs. These macromolecules display inherent adaptability of function, which is partly due to the production of different forms of the receptor protein. These are commonly called ‘isoforms’ or ‘splice variants’ denoting the molecular process of their production/ assembly. Not all GPCRs are expressed as splice variants, but certain subclasses of 5-HT receptors are for example, the 5-HT4 and 5-HT7 receptors. There are at least 11 human 5-HT4 and three h5-HT7 receptor splice variants. This review describes their discoveries, nomenclature and structures. The discovery that particular splice variants are tissue specific (or prominent) has highlighted their potential as future drug targets. In particular, this review examines the functional relevance of different 5-HT4 and 5-HT7 receptor splice variants. Examples are given to illustrate that splice variants have differential modulatory influences on signalling processes. Differences in agonist potency and efficacies and also differences in desensitisation rates to 5-HT occur with both 5-HT4 and 5-HT7 receptor splice variants. The known and candidate signalling systems that allow for splice variant specific responses include GPCR interacting proteins (GIPs) and GPCR receptor kinases (GRKs) which are examined. Finally, the relevance of 5-HT receptor splice variants to clinical medicine and to the pharmaceutical industry is discussed.
- 1 August 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (7) , 1012-1021
Activation of 5‐HT 3 receptors in the rat and mouse intestinal tract: a comparative study
This study provides a comprehensive evaluation of 5‐HT 3 receptor functional distribution in both the rat and mouse intestinal tract. 5‐HT 3A−S receptor splice variant mRNA was expressed throughout the intestine of the rat and mouse; the 5‐HT 3A−L variant being more common in the rat. 5‐HT, m‐CPB, 1‐PBG and 2‐methyl‐5‐hydroxytryptamine (2m5‐HT) induced contraction in the jejunum, ileum, proximal colon and distal colon of the rat (pEC 50 range: 2m5‐HT, 5.86±0.40 to m‐CPB, 7.47±0.27) and mouse (pEC 50 range: 1‐PBG, 5.34±0.06 to m‐CPB, 6.49±0.14) in the presence of nontarget 5‐HT receptor antagonists, methysergide (1 μ M ) and GR125487 (0.1 μ M ). The rank orders of potency in the four regions of the rat and mouse intestine were concordant with the accepted order and the responses to 5‐HT were inhibited by ondansetron (0.1 μ M ). 5‐HT 3 ‐induced contractions to 5‐HT were reduced by tetrodotoxin (1 μ M ). Pargyline (10 μ M ) and fluoxetine (1 μ M ) potentiated responses in the rat jejunum. Atropine (0.1 μ M ) potentiated 5‐HT 3 ‐induced responses in the rat jejunum ( E max 49–65%), but attenuated responses in most other regions of the rat and mouse (e.g. mouse ileum: E max 57–26%). In the rat jejunum, L ‐NAME (100 μ M ) mimicked the effect of atropine, hexamethonium (100 μ M ) suppressed 5‐HT 3 ‐induced responses, but tachykinin receptor antagonists were without effect. It is concluded that functional 5‐HT 3 receptors are present in nerves along the length of the rat and mouse intestinal tract. The mouse proximal colon was found to discriminate 5‐HT 3 receptor agonist profiles better than any other region in the rat or mouse. The rat jejunum shows evidence of 5‐HT uptake and inactivation processes as well as inhibitory nitrergic and nontachykinin excitatory pathways associated with the 5‐HT 3 ‐induced response. British Journal of Pharmacology (2006) 148 , 1012–1021. doi: 10.1038/sj.bjp.0706802
- 1 August 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (7) , 1012-1021
Activation of 5‐HT 3 receptors in the rat and mouse intestinal tract: a comparative study
This study provides a comprehensive evaluation of 5‐HT 3 receptor functional distribution in both the rat and mouse intestinal tract. 5‐HT 3A−S receptor splice variant mRNA was expressed throughout the intestine of the rat and mouse; the 5‐HT 3A−L variant being more common in the rat. 5‐HT, m‐CPB, 1‐PBG and 2‐methyl‐5‐hydroxytryptamine (2m5‐HT) induced contraction in the jejunum, ileum, proximal colon and distal colon of the rat (pEC 50 range: 2m5‐HT, 5.86±0.40 to m‐CPB, 7.47±0.27) and mouse (pEC 50 range: 1‐PBG, 5.34±0.06 to m‐CPB, 6.49±0.14) in the presence of nontarget 5‐HT receptor antagonists, methysergide (1 μ M ) and GR125487 (0.1 μ M ). The rank orders of potency in the four regions of the rat and mouse intestine were concordant with the accepted order and the responses to 5‐HT were inhibited by ondansetron (0.1 μ M ). 5‐HT 3 ‐induced contractions to 5‐HT were reduced by tetrodotoxin (1 μ M ). Pargyline (10 μ M ) and fluoxetine (1 μ M ) potentiated responses in the rat jejunum. Atropine (0.1 μ M ) potentiated 5‐HT 3 ‐induced responses in the rat jejunum ( E max 49–65%), but attenuated responses in most other regions of the rat and mouse (e.g. mouse ileum: E max 57–26%). In the rat jejunum, L ‐NAME (100 μ M ) mimicked the effect of atropine, hexamethonium (100 μ M ) suppressed 5‐HT 3 ‐induced responses, but tachykinin receptor antagonists were without effect. It is concluded that functional 5‐HT 3 receptors are present in nerves along the length of the rat and mouse intestinal tract. The mouse proximal colon was found to discriminate 5‐HT 3 receptor agonist profiles better than any other region in the rat or mouse. The rat jejunum shows evidence of 5‐HT uptake and inactivation processes as well as inhibitory nitrergic and nontachykinin excitatory pathways associated with the 5‐HT 3 ‐induced response. British Journal of Pharmacology (2006) 148 , 1012–1021. doi: 10.1038/sj.bjp.0706802
- 1 March 2005
- Published by Wiley in British Journal of Pharmacology
- Vol. 144 (5) , 687-694
Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum
1. The aim of the present investigation was to characterise the opioid receptor subtypes present in the rat ileum using a method that detects drug action on the enteric nerves innervating the circular and longitudinal muscles. 2. Neurogenic contractions were reversibly inhibited by morphine (circular muscle pEC50, 6.43+/-0.17, Emax 81.7+/-5.0%; longitudinal muscle pEC50, 6.65+/-0.27, Emax 59.7+/-7.8%), the mu-opioid receptor-selective agonist, DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin acetate) (circular pEC50, 7.85+/-0.04, Emax 97.8+/-3.6%; longitudinal pEC50, 7.35+/-0.09, Emax 56.0+/-6.1%), the delta-selective agonist DADLE ([D-Ala2,D-Leu5]enkephalin acetate) (circular pEC50, 7.41+/-0.17, Emax, 93.3+/-8.4%; longitudinal pEC50, 6.31+/-0.07, Emax 66.5+/-5.2%) and the kappa-selective agonist U 50488H (trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulphonate) (circular pEC50, 5.91+/-0.41, Emax, 83.5+/-26.8%; longitudinal pEC50, 5.60+/-0.08, Emax 74.3+/-7.2%). Agonist potencies were generally within expected ranges for activity at the subtype for which they are selective, except for U 50488H, which was less potent than expected. 3. The mu and delta receptor-selective antagonists, CTAP (H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) and naltrindole, caused progressive, parallel rightward shifts in the DAMGO and DADLE curves, respectively. Analysis indicated conformity to theoretical simple competitive antagonist behaviour. U 50488H effects were insensitive to the kappa-selective antagonist, n-BNI. A high concentration (1 microM) of naltrexone caused apparent potentiation of U 50488H effects. 4. CTAP pK(B) estimates were consistent with previously reported values for mu receptor antagonism (circular 7.84+/-0.17, longitudinal 7.64+/-0.35). However, the naltrindole pK(B) estimates indicated lower antagonist potency than expected (circular 8.22+/-0.23, longitudinal 8.53+/-0.35). 5. It is concluded that mu and possibly atypical delta receptors (but not kappa receptors) mediate inhibition of contraction in this model. Nonopioid actions of U 50488H are probably responsible for the inhibitory effects seen with this compound.
- 1 March 2005
- Published by Wiley in British Journal of Pharmacology
- Vol. 144 (5) , 687-694
Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum
1. The aim of the present investigation was to characterise the opioid receptor subtypes present in the rat ileum using a method that detects drug action on the enteric nerves innervating the circular and longitudinal muscles. 2. Neurogenic contractions were reversibly inhibited by morphine (circular muscle pEC50, 6.43+/-0.17, Emax 81.7+/-5.0%; longitudinal muscle pEC50, 6.65+/-0.27, Emax 59.7+/-7.8%), the mu-opioid receptor-selective agonist, DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin acetate) (circular pEC50, 7.85+/-0.04, Emax 97.8+/-3.6%; longitudinal pEC50, 7.35+/-0.09, Emax 56.0+/-6.1%), the delta-selective agonist DADLE ([D-Ala2,D-Leu5]enkephalin acetate) (circular pEC50, 7.41+/-0.17, Emax, 93.3+/-8.4%; longitudinal pEC50, 6.31+/-0.07, Emax 66.5+/-5.2%) and the kappa-selective agonist U 50488H (trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulphonate) (circular pEC50, 5.91+/-0.41, Emax, 83.5+/-26.8%; longitudinal pEC50, 5.60+/-0.08, Emax 74.3+/-7.2%). Agonist potencies were generally within expected ranges for activity at the subtype for which they are selective, except for U 50488H, which was less potent than expected. 3. The mu and delta receptor-selective antagonists, CTAP (H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) and naltrindole, caused progressive, parallel rightward shifts in the DAMGO and DADLE curves, respectively. Analysis indicated conformity to theoretical simple competitive antagonist behaviour. U 50488H effects were insensitive to the kappa-selective antagonist, n-BNI. A high concentration (1 microM) of naltrexone caused apparent potentiation of U 50488H effects. 4. CTAP pK(B) estimates were consistent with previously reported values for mu receptor antagonism (circular 7.84+/-0.17, longitudinal 7.64+/-0.35). However, the naltrindole pK(B) estimates indicated lower antagonist potency than expected (circular 8.22+/-0.23, longitudinal 8.53+/-0.35). 5. It is concluded that mu and possibly atypical delta receptors (but not kappa receptors) mediate inhibition of contraction in this model. Nonopioid actions of U 50488H are probably responsible for the inhibitory effects seen with this compound.
- 1 October 2003
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 30 (10) , 764-768
Effects of tachykinins and 5-hydroxytryptamine on intestinal secretion.
- 1 October 2003
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 30 (10) , 764-768
Effects of tachykinins and 5-hydroxytryptamine on intestinal secretion.
- 1 February 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (2) , 289-294
Effects of adenosine agonists on consumptive behaviour and body temperature
This study was designed to determine the effects of the A1-receptor selective agonist N6- cyclopentyladenosine (CPA), and the A2-selective agonist, 2-p-(2-carboxyethyl)-phenethyl-amino-5′-N-ethylcarboxamidoadenosine-hydrochloride (CGS-21680) on consumptive behaviour and body temperature in rats in relation to the non-selective A1/A2 adenosine agonist, N-ethylcarboxamidoadenosine (NECA), and to morphine. It was shown that two subcutaneous injections of 0.1 and 0.3 mg kg−1 CPA caused a similar decrease in food consumption to NECA (2 × 0.03 mg kg−1) and morphine (2 × 10 mg kg−1). However, two doses of 0.03 mg kg−1 CPA and 0.1 and 0.3 mg kg−1 CGS-21680 enhanced feeding. These effects were not directly correlated to faecal output at all doses of the selective agonists, as NECA and morphine induced constipation. The doses of CPA and 0.1 and 0.3 mg kg−1 of CGS-21680 enhanced water consumption, as did NECA, but not morphine. The stimulation of drinking by CPA was not absolutely associated with diuresis. Instead, urine output was reduced by 0.03 and 0.1 mg kg−1 and increased by 0.3 mg kg−1. CGS-21680 at 0.1 and 0.3 mg kg−1 and NECA also induced diuresis, which was opposite to the effect of morphine. CPA and CGS-21680 both caused significant dose-dependent decreases in body temperature after the two-injection treatment, but their effects were significantly less after 36 h when four doses had been administered. The study indicates that highly selective A1 and A2A adenosine agonists might have the ability to interfere with consumptive behaviour, induce constipation, affect renal function and to lower body temperature.
- 1 February 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (2) , 289-294
Effects of adenosine agonists on consumptive behaviour and body temperature
This study was designed to determine the effects of the A1-receptor selective agonist N6- cyclopentyladenosine (CPA), and the A2-selective agonist, 2-p-(2-carboxyethyl)-phenethyl-amino-5′-N-ethylcarboxamidoadenosine-hydrochloride (CGS-21680) on consumptive behaviour and body temperature in rats in relation to the non-selective A1/A2 adenosine agonist, N-ethylcarboxamidoadenosine (NECA), and to morphine. It was shown that two subcutaneous injections of 0.1 and 0.3 mg kg−1 CPA caused a similar decrease in food consumption to NECA (2 × 0.03 mg kg−1) and morphine (2 × 10 mg kg−1). However, two doses of 0.03 mg kg−1 CPA and 0.1 and 0.3 mg kg−1 CGS-21680 enhanced feeding. These effects were not directly correlated to faecal output at all doses of the selective agonists, as NECA and morphine induced constipation. The doses of CPA and 0.1 and 0.3 mg kg−1 of CGS-21680 enhanced water consumption, as did NECA, but not morphine. The stimulation of drinking by CPA was not absolutely associated with diuresis. Instead, urine output was reduced by 0.03 and 0.1 mg kg−1 and increased by 0.3 mg kg−1. CGS-21680 at 0.1 and 0.3 mg kg−1 and NECA also induced diuresis, which was opposite to the effect of morphine. CPA and CGS-21680 both caused significant dose-dependent decreases in body temperature after the two-injection treatment, but their effects were significantly less after 36 h when four doses had been administered. The study indicates that highly selective A1 and A2A adenosine agonists might have the ability to interfere with consumptive behaviour, induce constipation, affect renal function and to lower body temperature.
- 8 October 2001
- Published by Elsevier in Life Sciences
- Vol. 69 (21) , 2467-2475
Expression patterns of 5-HT7 receptor isoforms in the rat digestive tract.
- 8 October 2001
- Published by Elsevier in Life Sciences
- Vol. 69 (21) , 2467-2475
Expression patterns of 5-HT7 receptor isoforms in the rat digestive tract.
- 1 May 1997
- Published by Elsevier in General Pharmacology: The Vascular System
- Vol. 28 (5) , 709-713
Studies investigating the possible involvement of adenosine in the antisecretory action of morphine.
- 1 May 1997
- Published by Elsevier in General Pharmacology: The Vascular System
- Vol. 28 (5) , 709-713
Studies investigating the possible involvement of adenosine in the antisecretory action of morphine.